Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury

British Journal of Dermatology

Volumn 158, Issue 3, 2008, Pages 607-610

  Kalb, R E ^a   Helm, T N ^a   Sperry, H ^a   Thakral, C ^b   Abraham, J L ^b   Kanal, E ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Gadolinium; Kidney injury; Nephrogenic systemic fibrosis; Transient

Indexed keywords

CALCIUM; GADODIAMIDE; HYDROXYCHLOROQUINE; PHOSPHORUS; SODIUM; THALIDOMIDE;

ACUTE DISEASE; ADULT; ARTICLE; CASE REPORT; CEREBROVASCULAR DISEASE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NEPHROGENIC FIBROSING DERMOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; ROENTGEN SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SCLEROMYXEDEMA; SKIN BIOPSY;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SKIN; SKIN DISEASES; TREATMENT OUTCOME;

EID: 39049105128     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08369.x     Document Type: Article

References (19)

1. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006 21 : 1104 8.
2. Thomsen HS. European Society of Urogenital Radiology. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 2007 17 : 70 6.
3. Spencer A, Wilson S, Batchelor J et al. Gadolinium chloride toxicity in the rat. Toxicol Pathol 1997 25 : 245 55.
4. Cowper SE. Presentation at the 43rd American Society of Dermatopathology Meeting. Chicago, IL, 27 October 2006.
5. Cowper SE, Robin HS, Steinberg SM et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000 356 : 1000 1.
6. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003 139 : 903 9.
7. Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents. MMWR Morb Mortal Wkly Rep 2007 56 : 137 41.
8. Hellman RN. Erythropoietin, gadolinium, and nephrogenic fibrosing dermopathy. Ann Intern Med 2007 146 : 229 30.
9. Broome DR, Girguis MS, Baron PW et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007 188 : 586 92.
10. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007 56 : 27 30.
11. High WA, Ayers RA, Chandler J et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007 56 : 21 6.
12. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007 56 : 710 12.
13. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006 16 : 2619 21.
14. Sadowski EA, Bennett LK, Chan MR et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007 243 : 148 57.
15. Idée JM, Berthommier C, Goulas V et al. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. Biometals 1998 11 : 113 23.
16. Kanal E, Barkovich AJ, Bell C et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007 188 : 1447 74.
17. Kucher C, Xu X, Pasha T, Elenitsas R. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 2005 32 : 484 90.
18. Swaminathan S, Ahmed I, McCarthy JT et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006 145 : 234 5.
19. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006 17 : 2359 62.